SCHEMBL5249010

SCHEMBL5249010

CC(C)(C)C1OC(=O)OC1C(=O)O

nearest known ligand 0.35

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
SUCNR1 Q9BXA5 1/20 0.33
KAT2A Q92830 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18175949 0.77 SUCNR1 (0.47) SUCNR1KAT2A
SCHEMBL12389693 0.77
SCHEMBL21885984 0.71 SUCNR1 (0.38) SUCNR1KAT2A
SCHEMBL5197038 0.70 SUCNR1 (0.48) SUCNR1
SCHEMBL1440306 0.67
SCHEMBL28325988 0.67 PPM1B (0.36) SUCNR1KAT2A
SCHEMBL20365807 0.64
SCHEMBL11990743 0.64
SCHEMBL11990749 0.64
SCHEMBL16272964 0.64 MAPK1 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1740556-A1 HETEROCYCLIC ANTI-VIRAL COMPOUNDS COMPRISING METABOLIZABLE MOIETIES AND THEIR USES Rigel Pharmaceuticals, Inc. (US) 2007-01-10 EP disclosed
WO-2005097760-A1 HETEROCYCLIC ANTI-VIRAL COMPOUNDS COMPRISING METABOLIZABLE MOIETIES AND THEIR USES RIGEL PHARMACEUTICALS, INC. (US) 2005-10-20 WO disclosed